MAPT and Alzheimer disease: In 2018, the National Institute of Aging and Alzheimer’s Association (NIA-AA) defined a new method to unify the diagnosis of preclinical dementia, MCI and dementia due to AD in different stages, using the presence of Aβ, tau protein and neuronal injuries to classify patients into different profiles [6].